File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Antibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy

TitleAntibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy
Authors
Issue Date2014
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/
Citation
The 105th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, CA., 5-9 April 2014. In Cancer Research, 2014, v. 74 n. 19 suppl., abstract no. 3764 How to Cite?
AbstractThe novel growth factor granulin-epithelin precursor (GEP, also named progranulin, acrogranin, or PC-derived growth factor) has shown to be upregulated in breast, ovary, prostate, liver and various human cancers. Our group has shown that GEP associated with chemo-resistance, recurrence and cancer stem cell properties in liver cancer [Gastroenterology 2011 and PLoS One 2011]. In the current study, we demonstrated that, both in vivo and in vitro, liver cancer cells that survived after chemotherapeutic agents demonstrated up-regulation of hepatic cancer stem cell marker CD133/GEP/ABCB5, and enhanced cancer stem cell properties, including colony formation and spheroid formation abilities. Importantly, combination of GEP antibody therapy and chemotherapy reversed the phenotypes induced by chemotherapy alone in the liver cancer cells and also the chemo-resistant subpopulations. Notably, combination of GEP antibody and cisplatin resulted in the eradication of all established intrahepatic human xenografts. This preclinical study demonstrated that combination treatment has the potential to be effective therapeutic regimen for GEP positive cancers.
DescriptionConference Theme: Harnessing Breakthroughs - Targeting Cures
Session - Experimental and Molecular Therapeutics
Persistent Identifierhttp://hdl.handle.net/10722/201360
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorWong, CL-
dc.contributor.authorCheung, PFY-
dc.contributor.authorYip, CW-
dc.contributor.authorChan, KF-
dc.contributor.authorNg, IOL-
dc.contributor.authorFan, ST-
dc.contributor.authorCheung, ST-
dc.date.accessioned2014-08-21T07:25:24Z-
dc.date.available2014-08-21T07:25:24Z-
dc.date.issued2014-
dc.identifier.citationThe 105th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, CA., 5-9 April 2014. In Cancer Research, 2014, v. 74 n. 19 suppl., abstract no. 3764-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/201360-
dc.descriptionConference Theme: Harnessing Breakthroughs - Targeting Cures-
dc.descriptionSession - Experimental and Molecular Therapeutics-
dc.description.abstractThe novel growth factor granulin-epithelin precursor (GEP, also named progranulin, acrogranin, or PC-derived growth factor) has shown to be upregulated in breast, ovary, prostate, liver and various human cancers. Our group has shown that GEP associated with chemo-resistance, recurrence and cancer stem cell properties in liver cancer [Gastroenterology 2011 and PLoS One 2011]. In the current study, we demonstrated that, both in vivo and in vitro, liver cancer cells that survived after chemotherapeutic agents demonstrated up-regulation of hepatic cancer stem cell marker CD133/GEP/ABCB5, and enhanced cancer stem cell properties, including colony formation and spheroid formation abilities. Importantly, combination of GEP antibody therapy and chemotherapy reversed the phenotypes induced by chemotherapy alone in the liver cancer cells and also the chemo-resistant subpopulations. Notably, combination of GEP antibody and cisplatin resulted in the eradication of all established intrahepatic human xenografts. This preclinical study demonstrated that combination treatment has the potential to be effective therapeutic regimen for GEP positive cancers.-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/-
dc.relation.ispartofCancer Research-
dc.titleAntibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy-
dc.typeConference_Paper-
dc.identifier.emailWong, CL: nclwong@hku.hk-
dc.identifier.emailCheung, PFY: cphyllis@hkucc.hku.hk-
dc.identifier.emailYip, CW: wallacey@hku.hk-
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.emailCheung, ST: stcheung@hku.hk-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityFan, ST=rp00355-
dc.identifier.authorityCheung, ST=rp00457-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1158/1538-7445.AM2014-3764-
dc.identifier.hkuros233709-
dc.identifier.volume74-
dc.identifier.issue19 suppl., abstract no. 3764-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats